Premium
Adult genitourinary sarcoma: The era of optional chemotherapeutic agents for soft tissue sarcoma
Author(s) -
Urasaki Tetsuya,
Nakano Kenji,
Tomomatsu Junichi,
Komai Yoshinobu,
Yuasa Takeshi,
Yamashita Kyoko,
Takazawa Yutaka,
Yamamoto Shinya,
Yonese Junji,
Takahashi Shunji
Publication year - 2021
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.14417
Subject(s) - medicine , pazopanib , genitourinary system , sarcoma , soft tissue sarcoma , leiomyosarcoma , prostate , malignancy , surgery , oncology , univariate analysis , metastasis , cancer , pathology , multivariate analysis , sunitinib
Objective To report our institutional experience with treatment of primary genitourinary soft tissue sarcoma. Methods We retrospectively reviewed the medical records of adult soft tissue sarcoma patients treated between March 2005 and May 2019. The primary tumor sites included the prostate, kidney, urinary bladder and the paratesticular structures. Results A total of 19 patients – 16 men (84%) and three women (16%) – were enrolled in the study. The median age was 41 years (range 20–79 years). The most common primary site was the prostate (in eight patients; 42%), and prostatic sarcoma patients were younger than patients with sarcomas of other origins. The most common histological subtype was leiomyosarcoma (in five patients; 26%). The overall survival rates after 1, 3 and 5 years were 61.5%, 34.4% and 25.8%, respectively. The median survival time was 20.7 months (95% confidence interval 5.9–35.5 months). Univariate analysis showed that an absence of metastasis at diagnosis and complete surgical resection were predictive of favorable survival. In the chemotherapy group, the objective response rate was 20.5%. Pazopanib was administered to nine patients in the late‐line setting, and the objective response rate was 11.1%; six grade ≥3 adverse events were observed in three patients. Conclusions Inoperable metastatic genitourinary soft tissue sarcoma remains difficult to treat, as previously reported. Further investigation on this malignancy, including optimization of currently available antitumor drugs and the development of novel therapeutic agents, is required.